Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20%
of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free …

Summary Background Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately
13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a …

Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate
from the epithelial lining of the biliary tree. BTCs are characterized by presentation with …

Introduction Despite being commonly recommended, the impact of anticancer drugs (ACDs)
on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) …

Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line
treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently …

Prognosis of patients with advanced extrahepatic cholangiocarcinoma (eCCA) is poor. The
current standard first-line treatment is systemic chemotherapy (CT) with gemcitabine and a …

Simple Summary Treating biliary tract cancer (BTC) successfully remains to be a difficult
task. Standard therapeutic options encompass surgery, radiation and chemotherapy, but the …

Objective Prognosis of patients with irresectable cholangiocarcinoma is still poor. The ABC-
02 trial established the current first line (1L) standard systemic chemotherapy (CT) with …

Background: A systematic review was conducted to understand clinical, economic and
health-related quality-of-life outcomes in second-line biliary tract cancer. Materials & …

Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic
options, especially after the failure of first-line systemic treatment. Targeted treatments for …